Sharma, S. V., Bell, D. W., Settleman, J. & Haber, D. A. Epidermal expansion issue receptor mutations in lung most cancers. Nat. Rev. Most cancers 7, 169–181 (2007).
Brennan, C. W. et al. The somatic genomic panorama of glioblastoma. Mobile 155, 462–477 (2013).
An, Z., Aksoy, O., Zheng, T., Fan, Q. W. & Weiss, W. A. Epidermal expansion issue receptor and EGFRvIII in glioblastoma: signaling pathways and centered treatments. Oncogene 37, 1561–1575 (2018).
Wilson, Okay. J., Gilmore, J. L., Foley, J., Lemmon, M. A. & Riese, D. J., II. Purposeful selectivity of EGF circle of relatives peptide expansion elements: implications for most cancers. Pharmacol. Ther. 122, 1–8 (2009).
Freed, D. M. et al. EGFR ligands differentially stabilize receptor dimers to specify signaling kinetics. Mobile 171, 683–695 (2017).
Macdonald-Obermann, J. L. & Pike, L. J. Other epidermal expansion issue (EGF) receptor ligands display distinct kinetics and biased or partial agonism for homodimer and heterodimer formation. J. Biol. Chem. 289, 26178–26188 (2014).
Martínez-Jiménez, F. et al. A compendium of mutational most cancers driving force genes. Nat. Rev. Most cancers 20, 555–572 (2020).
Eck, M. J. & Yun, C. H. Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small mobile lung most cancers. Biochim. Biophys. Acta 1804, 559–566 (2010).
Tate, J. G. et al. COSMIC: {the catalogue} of somatic mutations in most cancers. Nucleic Acids Res. 47, D941–D947 (2019).
Heimberger, A. B. et al. Prognostic impact of epidermal expansion issue receptor and EGFRvIII in glioblastoma multiforme sufferers. Clin. Most cancers Res. 11, 1462–1466 (2005).
Eskilsson, E. et al. EGFR heterogeneity and implications for healing intervention in glioblastoma. Neuro Oncol. 20, 743–752 (2018).
Lee, J. C. et al. Epidermal expansion issue receptor activation in glioblastoma via novel missense mutations within the extracellular area. PLoS Med. 3, e485 (2006).
Ng, P. Okay. et al. Systematic useful annotation of somatic mutations in most cancers. Most cancers Mobile 33, 450–462 (2018).
Lu, C. et al. Structural proof for unfastened linkage between ligand binding and kinase activation within the epidermal expansion issue receptor. Mol. Mobile. Biol. 30, 5432–5443 (2010).
Garrett, T. P. J. et al. Crystal constitution of a truncated epidermal expansion issue receptor extracellular area certain to reworking expansion issue alpha. Mobile 110, 763–773 (2002).
Ferguson, Okay. M. Construction-based view of epidermal expansion issue receptor law. Annu. Rev. Biophys. 37, 353–373 (2008).
Ogiso, H. et al. Crystal constitution of the complicated of human epidermal expansion issue and receptor extracellular domain names. Mobile 110, 775–787 (2002).
Liebschner, D. et al. Polder maps: bettering OMIT maps by way of aside from bulk solvent. Acta Crystallogr. D Struct. Biol. 73, 148–157 (2017).
Diwanji, D. et al. Constructions of the HER2–HER3–NRG1β complicated divulge a dynamic dimer interface. Nature 600, 339–343 (2021).
Alvarado, D., Klein, D. E. & Lemmon, M. A. Structural foundation for unfavorable cooperativity in expansion issue binding to an EGF receptor. Mobile 142, 568–579 (2010).
Binder, Z. A. et al. Epidermal expansion issue receptor extracellular area mutations in glioblastoma provide alternatives for medical imaging and healing construction. Most cancers Mobile 34, 163–177 (2018).
Orellana, L. et al. Oncogenic mutations on the EGFR ectodomain structurally converge to take away a steric hindrance on a kinase-coupled cryptic epitope. Proc. Natl Acad. Sci. USA 116, 10009–10018 (2019).
Fan, Q. W. et al. EGFR phosphorylates tumor-derived EGFRvIII riding STAT3/5 and development in glioblastoma. Most cancers Mobile 24, 438–449 (2013).
An, Z. et al. EGFR cooperates with EGFRvIII to recruit macrophages in glioblastoma. Most cancers Res. 78, 6785–6794 (2018).
Friedmann-Morvinski, D. et al. Dedifferentiation of neurons and astrocytes by way of oncogenes can induce gliomas in mice. Science 338, 1080–1084 (2012).
Del Vecchio, C. A. et al. EGFRvIII gene rearrangement is an early tournament in glioblastoma tumorigenesis and expression defines a hierarchy modulated by way of epigenetic mechanisms. Oncogene 32, 2670–2681 (2013).
Emlet, D. R. et al. Focused on a glioblastoma most cancers stem-cell inhabitants outlined by way of EGF receptor variant III. Most cancers Res. 74, 1238–1249 (2014).
Alcantara Llaguno, S. et al. Mobile-of-origin susceptibility to glioblastoma formation declines with neural lineage restriction. Nat. Neurosci. 22, 545–555 (2019).
Jaiswal, B. S. et al. Oncogenic ERBB3 mutations in human cancers. Most cancers Mobile 23, 603–617 (2013).
Hopkins, J. B., Gillilan, R. E. & Skou, S. BioXTAS RAW: enhancements to a unfastened open-source program for small-angle X-ray scattering knowledge relief and research. J. Appl. Cryst. 50, 1545–1553 (2017).
Manalastas-Cantos, Okay. et al. ATSAS 3.0: expanded capability and new equipment for small-angle scattering knowledge research. J. Appl. Crystallogr. 54, 343–355 (2021).
Lemmon, M. A. et al. Two EGF molecules give a contribution additively to stabilization of the EGFR dimer. EMBO J. 16, 281–294 (1997).
Kabsch, W. XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125–132 (2010).
CCP4. The CCP4 suite: systems for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760–763 (1994).
McCoy, A. J. et al. Phaser crystallographic device. J. Appl. Cryst. 40, 658–674 (2007).
Emsley, P. & Cowtan, Okay. Coot: model-building equipment for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132 (2004).
Sensible, O. S. et al. Exploiting constitution similarity in refinement: automatic NCS and target-structure restraints in BUSTER. Acta Crystallogr. D Biol. Crystallogr. 68, 368–380 (2012).
Adams, P. D. et al. PHENIX: a complete Python-based gadget for macromolecular constitution answer. Acta Crystallogr. D Biol. Crystallogr. 66, 213–221 (2010).
Winn, M. D., Isupov, M. N. & Murshudov, G. N. Use of TLS parameters to mannequin anisotropic displacements in macromolecular refinement. Acta Crystallogr. D Biol. Crystallogr. 57, 122–133 (2001).
Chen, V. B. et al. MolProbity: all-atom constitution validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12–21 (2010).
Dawson, J. P. et al. Epidermal expansion issue receptor dimerization and activation require ligand-induced conformational adjustments within the dimer interface. Mol. Mobile. Biol. 25, 7734–7742 (2005).
Ferguson, Okay. M., Darling, P. J., Mohan, M. J., Macatee, T. L. & Lemmon, M. A. Extracellular domain names pressure homo- however now not hetero-dimerization of erbB receptors. EMBO J. 19, 4632–4643 (2000).
Essletzbichler, P. et al. Megabase-scale deletion the usage of CRISPR/Cas9 to generate a completely haploid human mobile line. Genome Res. 24, 2059–2065 (2014).
Kiyatkin, A., van Alderwerelt van Rosenburgh, I. Okay., Klein, D. E. & Lemmon, M. A. Kinetics of receptor tyrosine kinase activation outline ERK signaling dynamics. Sci. Sign. 13, eaaz5267 (2020).
Aksamitiene, E., Hoek, J. B. & Kiyatkin, A. Multistrip western blotting: a device for comparative quantitative research of more than one proteins. Strategies Mol. Biol. 1312, 197–226 (2015).
Gao, J. et al. Integrative research of complicated most cancers genomics and medical profiles the usage of the cBioPortal. Sci. Sign. 6, pl1 (2013).
Therneau, T. M. A bundle for survival research in R. https://CRAN.R-project.org/package=survival (2020).
Kohsaka, S. et al. A technique of high-throughput useful analysis of EGFR gene variants of unknown importance in most cancers. Sci. Transl. Med. 9, eaan6566 (2017).
Neelam, B. et al. Construction–serve as research of ligand-induced epidermal expansion issue receptor dimerization. Biochemistry 37, 4884–4891 (1998).
Thompson, S. A., Harris, A., Hoang, D., Ferrer, M. & Johnson, G. R. COOH-terminal prolonged recombinant amphiregulin with bioactivity similar with naturally derived expansion issue. J. Biol. Chem. 271, 17927–17931 (1996).
Adam, R. et al. Modulation of the receptor binding affinity of amphiregulin by way of amendment of its carboxyl terminal tail. Biochim. Biophys. Acta 1266, 83–90 (1995).
Bessman, N. J., Bagchi, A., Ferguson, Okay. M. & Lemmon, M. A. Advanced courting between ligand binding and dimerization within the epidermal expansion issue receptor. Mobile Rep. 9, 1306–1317 (2014).
Yu, S. et al. The non-small mobile lung most cancers EGFR extracellular area mutation, M277E, is oncogenic and drug-sensitive. Onco Objectives Ther. 10, 4507–4515 (2017).
Liu, P. et al. A unmarried ligand is enough to turn on EGFR dimers. Proc. Natl Acad. Sci. USA 109, 10861–10866 (2012).
Bessman, N. J., Freed, D. M. & Lemmon, M. A. Placing in combination buildings of epidermal expansion issue receptors. Curr. Opin. Struct. Biol. 29, 95–101 (2014).
Singh, B., Chippie, G. & Coffey, R. J. EGF receptor ligands: fresh advances. F1000Res. 5, 2270 (2016).
Macdonald, J. L. & Pike, L. J. Heterogeneity in EGF-binding affinities arises from unfavorable cooperativity in an aggregating gadget. Proc. Natl Acad. Sci. USA 105, 112–117 (2008).
Ferguson, Okay. M., Hu, C. & Lemmon, M. A. Insulin and epidermal expansion issue receptor members of the family proportion parallel activation mechanisms. Protein Sci. 29, 1331–1344 (2020).
Ferguson, Okay. M. et al. EGF turns on its receptor by way of taking out interactions that autoinhibit ectodomain dimerization. Mol. Mobile 11, 507–517 (2003).
Ramamurthy, V. et al. Constructions of adnectin/protein complexes divulge an expanded binding footprint. Construction 20, 259–269 (2012).
Matsuda, T. et al. Mobile-free synthesis of useful antibody fragments to supply a structural foundation for antibody-antigen interplay. PLoS ONE 13, e0193158 (2018).
Li, S. et al. Structural foundation for inhibition of the epidermal expansion issue receptor by way of cetuximab. Most cancers Mobile 7, 301–311 (2005).
Lee, J. J. et al. Enzymatic prenylation and oxime ligation for the synthesis of strong and homogeneous protein–drug conjugates for centered remedy. Angew. Chem. Int. Ed. Engl. 54, 12020–12024 (2015).
Alvarado, D., Klein, D. E. & Lemmon, M. A. ErbB2 resembles an autoinhibited invertebrate epidermal expansion issue receptor. Nature 461, 287–291 (2009).
#Glioblastoma #mutations #modify #EGFR #dimer #constitution #save you #ligand #bias
